Article ; Online: CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
Canadian journal of diabetes
2019 Volume 43, Issue 7, Page(s) 464–471
Abstract: Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting.: Methods: CANadian CAnagliflozin REgistry (CanCARE) is a ... ...
| Abstract | Objectives: To describe patient-reported outcomes (PROs) after initiation of treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a real-world Canadian setting. Methods: CANadian CAnagliflozin REgistry (CanCARE) is a prospective, observational, single-arm, real-world Canadian study of the effectiveness and safety of CANA for the treatment of T2DM in 527 subjects. PRO measures were collected in CanCARE using the Current Health Satisfaction Questionnaire (CHES-Q) at baseline and after 3, 6 and 12 months of CANA treatment to examine patient satisfaction regarding weight and overall health. Associations between changes in satisfaction with weight, systolic blood pressure (SBP) and glycated hemoglobin (A1C) levels were also investigated. Results: Proportion of patients satisfied with their body weight and overall health increased from 22.1% and 26.9% at baseline to 32.4% and 49.2% after 12 months of CANA treatment, respectively. Satisfaction rates also increased on CHES-Q domains representing physical and emotional health. Correlations were found between improvement in satisfaction with body weight and weight loss (r=-0.29; p<0.01) and between improvements in satisfaction with overall health and weight loss (r=-0.13; p=0.03) and SBP (r=-0.17; p<0.01), but not with changes in A1C level. Conclusions: Treatment with CANA is associated with improvements in satisfaction with body weight and overall health, which may be important drivers of patient self-management and hold the potential to positively influence long-term outcomes in T2DM. |
|---|---|
| MeSH term(s) | Blood Glucose/analysis ; Body Weight ; Canada ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Patient Reported Outcome Measures ; Practice Patterns, Physicians'/statistics & numerical data ; Prognosis ; Prospective Studies ; Registries/statistics & numerical data ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Surveys and Questionnaires ; Weight Loss |
| Chemical Substances | Blood Glucose ; Sodium-Glucose Transporter 2 Inhibitors ; Canagliflozin (0SAC974Z85) |
| Language | English |
| Publishing date | 2019-04-16 |
| Publishing country | Canada |
| Document type | Journal Article ; Observational Study |
| ISSN | 2352-3840 |
| ISSN (online) | 2352-3840 |
| DOI | 10.1016/j.jcjd.2019.04.004 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.